EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well EF5 works in measuring lack of tumor oxygen,
hypoxia, in patients with stage I-III non-small cell lung cancer. EF5 may be effective in
measuring the lack of oxygen in lung tumors and may allow doctors to plan better treatment.